Cancer has been a leading cause of death for decades. This dismal statistic has increased
efforts to prevent the disease or to detect it early, when treatment is less invasive, relatively …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

The APOBEC3 family of cytosine deaminases has been implicated in some of the most
prevalent mutational signatures in cancer,–. However, a causal link between endogenous …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC)
results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …

Clustered somatic mutations are common in cancer genomes and previous analyses reveal
several types of clustered single-base substitutions, which include doublet-and multi-base …

Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-
ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various …

Genome editing technologies operate by inducing site-specific DNA perturbations that are
resolved by cellular DNA repair pathways. Products of genome editors include DNA breaks …